![]() |
Name |
Laciniata furanone F
|
Molecular Formula | C14H20O3 | |
IUPAC Name* |
(2R,5R)-2-[(2S)-5-ethenyl-5-methyloxolan-2-yl]-5-prop-1-en-2-yloxolan-3-one
|
|
SMILES |
CC(=C)[C@H]1CC(=O)[C@H](O1)[C@@H]2CCC(O2)(C)C=C
|
|
InChI |
InChI=1S/C14H20O3/c1-5-14(4)7-6-11(17-14)13-10(15)8-12(16-13)9(2)3/h5,11-13H,1-2,6-8H2,3-4H3/t11-,12+,13-,14?/m0/s1
|
|
InChIKey |
JFVWSTQFYSQOMC-WJLOJVBCSA-N
|
|
Synonyms |
Laciniata furanone F
|
|
CAS | NA | |
PubChem CID | 91752787 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 236.31 | ALogp: | 2.2 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 35.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 17 | QED Weighted: | 0.706 |
Caco-2 Permeability: | -4.541 | MDCK Permeability: | 0.00002050 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.674 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.391 | Plasma Protein Binding (PPB): | 58.43% |
Volume Distribution (VD): | 1.325 | Fu: | 40.18% |
CYP1A2-inhibitor: | 0.034 | CYP1A2-substrate: | 0.796 |
CYP2C19-inhibitor: | 0.077 | CYP2C19-substrate: | 0.858 |
CYP2C9-inhibitor: | 0.034 | CYP2C9-substrate: | 0.089 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.5 |
CYP3A4-inhibitor: | 0.311 | CYP3A4-substrate: | 0.372 |
Clearance (CL): | 8.847 | Half-life (T1/2): | 0.59 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.517 |
Drug-inuced Liver Injury (DILI): | 0.244 | AMES Toxicity: | 0.503 |
Rat Oral Acute Toxicity: | 0.521 | Maximum Recommended Daily Dose: | 0.337 |
Skin Sensitization: | 0.368 | Carcinogencity: | 0.891 |
Eye Corrosion: | 0.515 | Eye Irritation: | 0.846 |
Respiratory Toxicity: | 0.849 |